Hypoxia-Activated Theragnostic Prodrugs (HATPs): Current State and Future Perspectives

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(4), P. 557 - 557

Published: April 19, 2024

Hypoxia is a significant feature of solid tumors and frequently poses challenge to the effectiveness tumor-targeted chemotherapeutics, thereby limiting their anticancer activity. Hypoxia-activated prodrugs represent class bio-reductive agents that can be selectively activated in hypoxic compartments unleash toxic warhead thus, eliminate malignant tumor cells. However, applicability further elevated by installing fluorescent modalities yield hypoxia-activated theragnostic (HATPs), which utilized for simultaneous visualization treatment The scope this review summarize noteworthy advances recent HATPs, highlight challenges opportunities development, discuss potency serve as personalized medicines future.

Language: Английский

Recent Progress in the Development of Peptide-Drug Conjugates (PDCs) for Cancer Therapy

European Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 284, P. 117204 - 117204

Published: Dec. 24, 2024

Language: Английский